VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MASI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MASIMasimo Corporation
$179.95$9.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

MASI logoMasimo Corporation(MASI)Earnings, Financials & Key Ratios

MASI•NASDAQ
$179.95
Price updated Jul 2, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryPatient monitoring and respiratory care
AboutMasimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.Show more
  • Revenue$1.53B-27.1%
  • EBITDA$352M+314.8%
  • Net Income-$152M+50.3%
  • EPS (Diluted)-2.80+51.0%
  • Gross Margin61.9%+29.1%
  • EBITDA Margin23.03%+394.6%
  • Operating Margin20.49%+260.9%
  • Net Margin-9.92%+31.8%
  • ROE-17.09%+32.3%

MASI Price & Volume

Masimo Corporation (MASI) stock price & volume — 10-year historical chart

Loading chart...

Consumer Integration Volatility Strains Core Profitability

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Adequate
Cash Flow:Mixed
Primary Risk:Consumer segment integration volatility

Key Thesis Takeaways

  • Masimo faces a complex transition as it attempts to reconcile its high-margin clinical monitoring business with the lower-margin consumer audio segment, leading to significant earnings volatility and margin compression.
  • While the company has successfully reduced its total debt from $970.0M in 2023Q4 to $485.9M in 2026Q1, the persistent decoupling of operating cash flow from net income suggests ongoing challenges in operational execution.
  • Investors should monitor whether the recent stabilization of operating margins at 19.2% in 2026Q1 can be sustained without further goodwill impairments, which have already dropped from $407.7M to $100.9M over the same period.

Verdict Logic

while the company has successfully deleveraged its balance sheet to $485.9M in total debt, the forward P/E of 32.73 appears high given the historical volatility in net income and the ongoing integration risks of the consumer segment.

MASI Growth Metrics

Masimo Corporation (MASI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years9.25%
5 Years5.95%
3 Years-9.14%
TTM-14.42%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM115.43%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM115.84%

Return on Capital

10 Years21.11%
5 Years8.01%
3 Years4.09%
Last Year18.76%

MASI Recent Earnings

Masimo Corporation (MASI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$1.43+1.4%
$1.41
Rev
$400M+0.2%
$399M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.18-87.8%
$1.48
Rev
$413M+1.1%
$408M
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$1.32+10.9%
$1.19
Rev
$372M-8.9%
$408M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$1.33+8.1%
$1.23
Rev
$371M+0.5%
$369M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$1.43vs $1.41+1.4%
$400Mvs $399M+0.2%
Q1 2026Feb 26, 2026
$0.18vs $1.48-87.8%
$413Mvs $408M+1.1%
Q4 2025Nov 4, 2025
$1.32vs $1.19+10.9%
$372Mvs $408M-8.9%
Q3 2025Aug 5, 2025
$1.33vs $1.23+8.1%
$371Mvs $369M+0.5%
Based on last 12 quarters of dataView full earnings history →

Latest MASI News

Recent stock market news and headlines for Masimo Corporation (MASI)

Business Wire·Jun 22, 2026
Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner

IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--Masimo smartSET™-powered, AI-enabled OIRD detection has received FDA 510(k) clearance for the Radius VSM® wearable continuous patient monitor.

Peers Comparison

Key metrics vs top competitors for Masimo Corporation (MASI)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MASI logoMASIMasimo CorporationCurrent
$179.95$9.42B-64.27-27.1%-9.92%-17.09%—
PODD logoPODDInsulet Corporation
$161.55$11.34B46.4230.73%10.44%21.38%—
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
ITGR logoITGRInteger Holdings Corporation
$91.90$3.16B31.807.57%7.67%8.23%—
ICUI logoICUIICU Medical, Inc.
$155.37$3.88B5284.69-6.38%2.15%2.19%—

Compare MASI vs Peers

Masimo Corporation (MASI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PODD

Most directly comparable listed peer for MASI.

Scale Benchmark

vs AAPL

Larger-name benchmark to compare MASI against a more recognizable public peer.

Peer Set

Compare Top 5

vs PODD, HOLX, NVCR, ITGR

MASI SEC Filings & Documents

Masimo Corporation (MASI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 4, 2026·SEC

Material company update

Apr 23, 2026·SEC

Material company update

Feb 17, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 5, 2025·SEC

Get notified when MASI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MASI Frequently Asked Questions

Masimo Corporation (MASI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Masimo Corporation's revenue?

Masimo Corporation (MASI) reported $1.56B in revenue for fiscal year 2025. This represents a 91576% increase from $1.7M in 1998.

How fast is Masimo Corporation growing?

Masimo Corporation (MASI) saw revenue decline by 27.1% over the past year.

Is MASI profitable?

Yes, Masimo Corporation (MASI) is profitable, generating $76.3M in net income for fiscal year 2025 (-9.9% net margin).

Dividend & Returns
What is MASI's return on equity?

Masimo Corporation (MASI) has a return on equity (ROE) of -17.1%. Negative ROE indicates the company is unprofitable.

What is Masimo Corporation's free cash flow?

Masimo Corporation (MASI) generated $211.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in MASI back in 1998?

Total return calculator · dividends reinvested · 28+ years of data

See returns →